BR0111264A - Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização - Google Patents

Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização

Info

Publication number
BR0111264A
BR0111264A BR0111264-3A BR0111264A BR0111264A BR 0111264 A BR0111264 A BR 0111264A BR 0111264 A BR0111264 A BR 0111264A BR 0111264 A BR0111264 A BR 0111264A
Authority
BR
Brazil
Prior art keywords
factor viia
compounds
formula
derivatives
preparation
Prior art date
Application number
BR0111264-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Otmar Klingler
Manfred Schudok
Hans-Peter Nestler
Hans Matter
Herman Schreuder
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0111264A publication Critical patent/BR0111264A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR0111264-3A 2000-06-06 2001-05-26 Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização BR0111264A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00112116A EP1162194A1 (en) 2000-06-06 2000-06-06 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
PCT/EP2001/006029 WO2001094301A2 (en) 2000-06-06 2001-05-26 Factor viia inhibitory (thio)urea derivatives, their preparation and their use

Publications (1)

Publication Number Publication Date
BR0111264A true BR0111264A (pt) 2003-06-17

Family

ID=8168926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111264-3A BR0111264A (pt) 2000-06-06 2001-05-26 Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização

Country Status (29)

Country Link
US (1) US6743790B2 (enExample)
EP (2) EP1162194A1 (enExample)
JP (1) JP4809570B2 (enExample)
KR (1) KR101011345B1 (enExample)
CN (1) CN1208314C (enExample)
AR (1) AR030936A1 (enExample)
AU (2) AU7749401A (enExample)
BR (1) BR0111264A (enExample)
CA (1) CA2410862C (enExample)
CZ (1) CZ20023963A3 (enExample)
DE (1) DE60139320D1 (enExample)
DK (1) DK1299354T3 (enExample)
EE (1) EE200200617A (enExample)
ES (1) ES2330412T3 (enExample)
HR (1) HRP20020961A2 (enExample)
HU (1) HUP0301631A2 (enExample)
IL (2) IL153220A0 (enExample)
MX (1) MXPA02009789A (enExample)
MY (1) MY129363A (enExample)
NO (1) NO328546B1 (enExample)
NZ (1) NZ522960A (enExample)
PL (1) PL359584A1 (enExample)
PT (1) PT1299354E (enExample)
RU (1) RU2286337C2 (enExample)
SK (1) SK17032002A3 (enExample)
TW (1) TWI283662B (enExample)
WO (1) WO2001094301A2 (enExample)
YU (1) YU89202A (enExample)
ZA (1) ZA200209018B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483228C (en) 2002-04-27 2011-07-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Carboxamides
US7122580B2 (en) * 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
AU2004249670A1 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Acylsulfamide inhibitors of factor VIIa
JP2007500221A (ja) * 2003-05-20 2007-01-11 ジェネンテック・インコーポレーテッド 第VIIa因子のベンゾフラン阻害剤
US7544699B2 (en) * 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
EP1810965A4 (en) * 2004-10-13 2009-10-28 Eisai R&D Man Co Ltd HYDRAZIDE DERIVATIVES
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US20090041747A1 (en) * 2005-02-24 2009-02-12 Novo Nordisk Health Care Ag Compounds for Stabilizing Factor VII Polypeptide Formulations
US20080312161A1 (en) * 2005-02-24 2008-12-18 Anders Klarskov Petersen Compounds For Stabilizing Factor VII Polypeptide Formulations
JP2008531523A (ja) * 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Vii因子ポリペプチド製剤を安定化する化合物
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP2000465B1 (en) 2006-03-24 2010-12-15 Eisai R&D Management Co., Ltd. Triazolone derivative
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
JPWO2009038157A1 (ja) * 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 2,3−ジヒドロ−イミノイソインドール誘導体
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
SG11201406629VA (en) * 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
WO2014057069A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide
EP2964213B1 (en) 2013-03-06 2020-11-04 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
AU2014226001B2 (en) 2013-03-06 2018-12-06 Allergan, Inc. Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH06505978A (ja) * 1991-02-05 1994-07-07 スミスクライン・ビーチャム・コーポレイション 芳香族エステルまたはアミドを含有する抗凝集性ペプチド
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
JP3387948B2 (ja) * 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
GB9313269D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Allophanic acid derivatives
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists
WO1995011228A1 (en) * 1993-10-19 1995-04-27 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionic acid derivative
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
AU712504B2 (en) * 1996-01-30 1999-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0004200A3 (en) * 1997-11-18 2001-04-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and their use as drugs
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
AU2001277494B2 (en) 2006-05-04
CA2410862C (en) 2009-11-10
IL153220A (en) 2008-11-03
DK1299354T3 (da) 2009-11-16
NO20025810L (no) 2002-12-03
MY129363A (en) 2007-03-30
HK1055941A1 (en) 2004-01-30
EP1299354B1 (en) 2009-07-22
HUP0301631A2 (hu) 2003-09-29
US6743790B2 (en) 2004-06-01
JP2003535844A (ja) 2003-12-02
AR030936A1 (es) 2003-09-03
EP1162194A1 (en) 2001-12-12
NZ522960A (en) 2004-05-28
PT1299354E (pt) 2009-10-01
NO328546B1 (no) 2010-03-15
IL153220A0 (en) 2003-07-06
CA2410862A1 (en) 2001-12-13
WO2001094301A2 (en) 2001-12-13
CN1427818A (zh) 2003-07-02
ES2330412T3 (es) 2009-12-10
WO2001094301A3 (en) 2002-04-04
KR101011345B1 (ko) 2011-01-28
TWI283662B (en) 2007-07-11
YU89202A (sh) 2006-05-25
DE60139320D1 (de) 2009-09-03
CN1208314C (zh) 2005-06-29
EP1299354A2 (en) 2003-04-09
NO20025810D0 (no) 2002-12-03
HRP20020961A2 (en) 2004-12-31
US20020052417A1 (en) 2002-05-02
AU7749401A (en) 2001-12-17
SK17032002A3 (sk) 2003-05-02
MXPA02009789A (es) 2003-03-12
ZA200209018B (en) 2003-10-08
RU2286337C2 (ru) 2006-10-27
JP4809570B2 (ja) 2011-11-09
CZ20023963A3 (cs) 2003-03-12
PL359584A1 (en) 2004-08-23
KR20030007911A (ko) 2003-01-23
EE200200617A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
YU89202A (sh) Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba
PT1349847E (pt) Novos derivados de oxibenzamidas como inibidores do factor xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
UY28325A1 (es) Nuevos derivados de indol como inhibidores del factor xa
DK1423357T3 (da) Urinstofderivater med antiproteolytisk aktivitet
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
BR0011461A (pt) Inibidores do fator viia
BR0012610A (pt) Novo derivado de difenilpiperidina
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
TR199801229T2 (xx) ''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
EP0620737B1 (en) Use of LACTOFERRIN iN the manufacture of a medicament for treating RHEUMATISM
BRPI0410446A (pt) derivados de benzimidazol como inibidores de fator xa
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
US2491489A (en) Therapeutic composition of sulfonamides
JPS61277614A (ja) 抗プラスミン剤

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time